Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

University Medicine Berlin, Berlin

AO Città della Salute e della Scienza di Torino, Torino

National Institute of Endocrinology, Bucharest

CHU de la Timone, Marseille

IRCCS AOU San Martino-IST, University of Genova, Genova

University Medical Center Hamburg-Eppendorf, Hamburg

CHU le BOCAGE, Dijon

Hospital Ramon y Cajal, Madrid

Hôpital Haut Lévêque, Pessac

Azienda Ospedaliera Padova, Padua

Hospital Universitario Virgen del Rocio, Seville

Azienda Ospedaliera Universitaria Senese, Siena

Ospedale Cisanello, Pisa

Policlinico of Palermo, Palermo

Hôpital de Bicêtre (AP-HP), Le Kremlin-Bicêtre

Endocrinological Research Center Ministry of Health Russian Federation, Moscow

Federal State Budgetary Military, Saint Petersburg

North-Western State Medical University, Saint Petersburg

Kazan state Medical Academy, Kazan'

Healthcare Institution, Nizhny Novgorod

Kemerovo Regional Clinical Hospital, Kemerovo

Antwerp University Hospital, Edegem

Domaine Universitaire Sart Tilman, Liège

Fakultni nemocnice u sv. Anny v Brne, Brno

Fakultní nemocnice Hradec Králové (University Hospital Hradec), Hradec Králové

Lithuanian University of Health Sciences (LUHS) Kauno klinikos, Kaunas

Vilnius University hospital Santariskiu Klinikos, Vilnius

Erasmus University Medical Centre Rotterdam, Rotterdam

Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok

Szpital Kliniczny im. H. Święcickiego UM w Poznaniu, Poznan

Szpital Bielanski im. ks. Jerzego Popieluszki SPZOZ, Warsaw

Szpital Kliniczny nr 1, Wroclaw

Hospital Universitario Vall d' Hebron, Barcelona

Queen Mary, University of London, London

Christie NHS Foundation Trust, Manchester

Churchill Hospital, Oxford